Skip to content
TrialScanner

NCT07197580

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Phase 3RecruitingMEDPCollaborator

Registry record

Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Conditions
ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC); Renal Cell Cancer Metastatic; Renal Cell Cancer, Recurrent
Primary completion
Aug 31, 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07197580 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07197580: Phase 3 Study to Assess... | TrialScanner